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Abstract
Background: A large number of distinct mutations in the BRCA1 and BRCA2 genes have been reported worldwide, but
little is known regarding the role of these inherited susceptibility genes in breast cancer risk among Indian women. We
investigated the distribution and the nature of BRCA1 and BRCA2 germline mutations and polymorphisms in a cohort of
204 Indian breast cancer patients and 140 age-matched controls.
Method: Cases were selected with regard to early onset disease (≤40 years) and family history of breast and ovarian
cancer. Two hundred four breast cancer cases along with 140 age-matched controls were analyzed for mutations. All
coding regions and exon-intron boundaries of the BRCA1 and BRCA2 genes were screened by heteroduplex analysis
followed by direct sequencing of detected variants.
Results: In total, 18 genetic alterations were identified. Three deleterious frame-shift mutations (185delAG in exon 2;
4184del4 and 3596del4 in exon 11) were identified in BRCA1, along with one missense mutation (K1667R), one 5'UTR
alteration (22C>G), three intronic variants (IVS10-12delG, IVS13+2T>C, IVS7+38T>C) and one silent substitution
(5154C>T). Similarly three pathogenic protein-truncating mutations (6376insAA in exon 11, 8576insC in exon19, and
9999delA in exon 27) along with one missense mutation (A2951T), four intronic alterations (IVS2+90T>A, IVS7+75A>T,
IVS8+56C>T, IVS25+58insG) and one silent substitution (1593A>G) were identified in BRCA2. Four previously reported
polymorphisms (K1183R, S1613G, and M1652I in BRCA1, and 7470A>G in BRCA2) were detected in both controls and
breast cancer patients. Rare BRCA1/2 sequence alterations were observed in 15 out of 105 (14.2%) early-onset cases
without family history and 11.7% (4/34) breast cancer cases with family history. Of these, six were pathogenic protein
truncating mutations. In addition, several variants of uncertain clinical significance were identified. Among these are two
missense variants, one alteration of a consensus splice donor sequence, and a variant that potentially disrupts
translational initiation.
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Conclusion: BRCA1 and BRCA2 mutations appear to account for a lower proportion of breast cancer patients at
increased risk of harboring such mutations in Northern India (6/204, 2.9%) than has been reported in other populations.
However, given the limited extent of reported family history among these patients, the observed mutation frequency is
not dissimilar from that reported in other cohorts of early onset breast cancer patients. Several of the identified
mutations are unique and novel to Indian patients.
Background
Breast cancer is the most prevalent malignancy and pri-
mary cause of cancer death in women worldwide. It
accounts for 23% of all cancers among women, and is the
second most common cancer overall when both sexes are
considered together. Despite substantial differences in
age-standardized incidence rates between developed and
developing countries (age standardised rates per 100,000
women (ASR) ranging from 99.4 to 16.5 in North Amer-
ica and Central Africa, respectively), differential survival
in developed versus developing countries diminishes the
range observed in corresponding mortality rates (ASR of
19.2 in North America vs. 12.1 in Central Africa). In all,
breast cancer accounts for 14.1% of female cancer deaths.
Most alarmingly, incidence rates have continued to
increase worldwide, with an overall annual increase of
approximately 0.5% since 1990. However, changes in
incidence rates are greatest in developing countries,
attaining annual increases of 3–4%. Should these trends
continue, it is estimated that 1.5 million new cases of
breast cancer will be diagnosed in 2010 [1].
In India, an average of 80,000 women are diagnosed with
carcinoma of the breast, and 40,000 women die of the dis-
ease every year [2]. Although it is currently the second
most common cancer among Indian women (19%) after
cervical cancer (30%), in the urban cancer registries of
Delhi and Mumbai, breast cancer has rapidly overtaken
cervical cancer in frequency. The highest cancer incidence
rate recorded among women at the Delhi Cancer Registry
is breast cancer (ASR 30.5). These data not only demon-
strate the magnitude of the current health problem associ-
ated with breast cancer in the Indian population, but also
indicate that socio-economic trends will lead to rapid
increases in its contribution to the overall health care bur-
den.
Interestingly, although overall incidence of breast cancer
in Indian population is low compared to Western popula-
tions (ASR of 23.5 vs. 90.7), the incidence of early onset
disease (< 40 yrs) does not show significant geographic
variation (ASR range worldwide of 12–33) [3] suggesting
that in the Indian population a greater proportion of
breast cancer is due to early onset disease compared to
Western populations. According to the National Cancer
Registry Project [NCRP] based on cancer registries at six
hospitals, the average age of patients was found to range
from 44.2 years (Dibrugarh) to 49.6 years (Bangalore and
Chennai) [4]. Similarly, the average age of breast cancer
patients in various population-based registries through-
out India has been reported to be 50–53 years [5] whereas
amongst US white females it is 61.0 years [6] showing that
in Indian women, disease occurs a decade earlier than in
Western populations.
Several environmental risk factors that may contribute to
or hasten the development of breast cancer have been
identified, including mainly lifestyle and reproductive fac-
tors. These may account for the majority of observed
trends and the variation in incidence rates between devel-
oped and developing countries. The factor with the
strongest breast cancer risk association is a family history
of breast and/or ovarian cancer, the associated risk being
even higher for family history of early onset disease (≤ age
40). The majority of familial breast cancer cases present at
an early age relative to sporadic cancer, and genetic factors
are considered to play major role in their development.
Hence, the earlier average age of breast cancer among
Indian women is intriguing, suggestive of a significant
genetic component in this population.
Genetic susceptibility to cancer is triggered in several
ways, the best understood causal mechanism being due to
inactivating germline mutations in tumor suppressor and
DNA repair genes, which lead to an accumulation of
mutations in oncogenes and cell-cycle checkpoints that
are required for uncontrolled cell division. About 5–10%
of breast and ovarian cancer occurs as a result of highly
penetrant germline mutations. Two major breast cancer
susceptibility genes are BRCA1 (MIM 113705, Genbank
accession no. U14680) and BRCA2 (MIM 600185, Gen-
bank accession no. U43746), located on long arms of
chromosomes 17 [7] and 13 [8], respectively. and both
apparently function as tumor suppressor genes. BRCA1 is
a large protein of 1863 amino acids and BRCA2, with
3418 amino acids, is even larger. Both the proteins are
involved in control of homologous recombination (HR)
and double-strand break repair in response to DNA dam-
age [9-14].
Mutations in the BRCA1  and  BRCA2  genes were first
reported in conjunction with their identification in 1994
[15] and 1995 [16,17]. To date 1536 distinct mutations,
polymorphisms and variants in BRCA1  and 1885 inBMC Medical Genetics 2006, 7:75 http://www.biomedcentral.com/1471-2350/7/75
Page 3 of 12
(page number not for citation purposes)
BRCA2 have been reported [BIC database, [18]], which are
distributed throughout the entire coding regions of both
genes. Together, mutations in both the genes account for
the great majority of families with hereditary susceptibil-
ity to breast and ovarian cancer [19].
Epidemiological studies indicate that BRCA1  mutation
carriers have a lifetime risk of breast cancer that is on the
order of 60–80% [19-21]. The lifetime breast cancer risk
for BRCA2 mutation carriers approaches that of BRCA1
carriers: however, disease onset has been documented to
be at a later age [19,21]. In other words, women with an
altered BRCA1 or BRCA2 gene are 3 to 7 times more likely
to develop breast cancer than women without alterations
in those genes [22], with very high relative risks for early
disease onset (before age 40) of about 30-fold. Carriers of
BRCA1 and BRCA2 mutation(s) are also at increased risk
for other cancers – in particular, both genes increase the
risk of ovarian cancer, while BRCA2  confers greatly
increased risks of male breast cancer. Additional, but
more modest risks are found for uterine, cervical, early-
onset prostate and pancreatic cancers for BRCA1 [23], and
prostatic, pancreatic, gallbladder, bile duct, stomach can-
cers and melanoma for BRCA2 [24].
The spectrum of BRCA1 and BRCA2 mutations has been
characterized in different populations worldwide, with
significant variation of the relative contribution of these
genes to hereditary cancer between populations and
examples of population specific founder mutations
(BRCA1: 185delAG, 5382insC, BRCA2:6174delT in Jews,
BRCA2: 999del5 in the Icelandic population) [reviewed in
[25]]. However, the contribution of mutations in these
two genes to breast cancer patients in the Indian popula-
tion remains relatively unexplored apart from a few small
studies [26-30]. Hence there is a need for screening a
larger number of samples to investigate the role of BRCA1/
BRCA2 gene mutations in the high-risk group of familial
as well as early onset cases, which forms the largest group
of breast cancer patients in the Indian population.
We have screened 204 breast cancer cases from North
India for mutations throughout the entire coding region
of both genes. The main focus behind the study is to pro-
vide reliable hospital based estimates of genetic influence,
and to characterize the nature and prevalence of BRCA1
and BRCA2 germline mutations in early-onset and famil-
ial breast cancer cases.
Methods
Case selection
Two hundred and four patients of breast cancer referred
from the department(s) of Surgery and Cancer Surgery
Safdarjung Hospital, New Delhi and LLRM Medical Col-
lege Meerut during 1999–2003 were selected for the
study.
Selection of patients was mainly based on the following
criteria: any patient with breast cancer diagnosed under
the age of 40 years; any patient having a family history of
breast or ovarian cancer; any patient having a previous
personal history of ovarian cancer; and any male patient
with or without family history. However, a few patients
unslected for age of onset or family history were also
included.
The study group included total 204 patients (Table 1);
105(51.4%) early onset, 65(31.8%) late onset and 34
(16.6%) familial cases. Out of 204, 11 cases are bilateral
(5 synchronous, 6 metachronous) and 8 are male breast
cancer cases.
The patient's ages ranged from 13 to 78 years with a mean
age of 40.9 years (median 40 years). Informed consent
was obtained from all participating patients and the study
was carried out with the approval of Ethical Review Com-
mittee of Safdarjung Hospital, New Delhi.
To examine the population frequency of any sequence
variants identified in the patients, a series of 140  age-
matched control samples were also collected from women
attending antenatal checkups and blood bank donors in
Delhi. The majority of control individuals were under 45
years (77%) and 71% were females.
Table 1: Characteristics of Breast carcinoma patients.
Age group of patients Total number of patients Familial cases Mutation positive cases (known deleterious mutations only)
BRCA1 BRCA2 Total
F.H. no F.H. F.H. no F.H.
≤ 40 121 17 (14%) 0 2 (1.9%) 0 2 (1.9%) 4 (3.3%)
>40 83 17 (20.5%) 1 (5.9%) 0 0 1 (1.5%) 2 (2.4%)
Total 204 34 (16.7%) 1 2 0 3 6 (2.9%)
F.H. – family history; no F.H. – without reported family history.BMC Medical Genetics 2006, 7:75 http://www.biomedcentral.com/1471-2350/7/75
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Blood sample collection
Peripheral blood samples (ca.10 ml) were collected into
EDTA vials. The buffy coat was separated and frozen at -
70°C for further use.
Genomic DNA was extracted from peripheral blood lym-
phocytes using a standard phenol-chloroform extraction
method. Blood was first digested with lyses buffer I (30
mM Tris, 5 mM EDTA and 50 mM NaCl) and lyses buffer
II (20% SDS, 100 µg/ml Prot.K) followed by the extrac-
tion with Tris saturated phenol and Chloroform-isoamyl
alcohol (24:1) and finally recovered by ethanol precipita-
tion.
Mutation detection
The complete coding regions and exon-intron boundaries
for both BRCA1 and BRCA2 genes were screened for DNA
sequence variants by Heteroduplex analysis (HDX) of
PCR amplicons using exon specific primers [31].
PCR reactions were carried out in a volume of 15 µl with
70–100 ng genomic DNA, 1× PCR buffer (20 mM Tris-Hcl
pH 8.4,50 mM KCl), 1.5 mM MgCl2, 5 mM dNTP mix, 10
µM of both forward and reverse primer, 0.2 U platinum
Taq (Invitrogen) and 0.4 µCi [α-P33] dATP (BRIT, Depart-
ment of Atomic Energy, India). An initial de-naturation of
94°C for 3 min was followed by 40 cycles of amplification
(30 s/94°C, 30 s/primer specific annealing temperature,
and 30 s/72°C) and final elongation of 3 min/74°C.
Samples were diluted 1:1 in formamide dye (98% forma-
mide, 10 mM NaOH, 0.05% bromophenol blue and
0.05% xylene cyanol) and 5 µl of each was loaded onto a
HDX gel (40 × 40 cm; containing 0.5× MDE, 0.6× TBE, 4%
glycerol, 400 µl 10%APS, 40 µl TEMED) and run at 8–10
mA for 16–20 hrs in 0.6× TBE at room temperature.
Gels were dried under vacuum at 80°C for 2 hrs and
exposed to film (KODAK BioMax-MR Amersham, USA)
for 10–12 hrs with an intensifying screen.
To rule out the possibility of PCR fidelity artefacts, both
PCR amplification and gel based heteroduplex analysis
was done twice for samples that showed altered mobility
on HDX gels.
PCR products showing an aberrant banding pattern were
re-amplified for sequencing using the same primers as for
HDX analysis. DNA samples were sequenced either man-
ually (Sequenase PCR Product Sequencing Kit and [α-
33P] dATP (Amersham Life science) according to manu-
facturer's instruction) and by Automated genetic analysis
(ABI 310/3100, Applied Biosystems, CA) to determine the
exact sequence alteration identified. Samples were
sequenced in both the forward and reverse sense to cor-
roborate the findings.
Results and discussion
The incidence of breast cancer in India has been increas-
ing in recent years and is likely to pose an ever-increasing
health care burden as socio-economic changes bring
about increased exposure to lifestyle risk factors. The ear-
lier average age of onset among Indian women compared
to Western populations and the increased likelihood of
early-onset disease being attributable to genetic suscepti-
bility suggests the existence of a strong genetic component
in this population. Evaluation of age of onset and family
history among breast cancer patients diagnosed in Safdar-
jung Hospital, New Delhi supports these observations.
Mean age of onset for 569 women diagnosed with breast
cancer during 1989–2003 was 47.8 years, with the most
common age group consisting of women 45–54 years
(31.8%). Approximately 22% of cases were diagnosed
under the age of 40 years. Of the 226 cases for whom fam-
ily history information was available, 47 (20.7%)
reported at least one additional breast or ovarian cancer
case in first or second-degree relatives [32]. To determine
the contribution of BRCA1 and BRCA2 to breast cancer in
women of North India, we screened for alterations in the
coding sequences and intron-exon boundaries of both
genes in 204 breast cancer patients and 140 age-matched
controls. This represents the largest study to date of the
BRCA genes in the Indian population.
Sequence variants in BRCA 1 & 2 genes
In total, 18 sequence variants were identified in the study
group, including 3 frame shift (FS), 1 missense (MS), 1
5'UTR alteration, 1 silent substitution, and 3 intronic var-
iants in BRCA1 (Table 2) and 3 FS, 1 MS, 1 silent and 4
intronic variants in the BRCA 2 gene (Table 3).
Additional sequence variants detected in this study
included 4 common polymorphisms (BRCA1: K1183R in
exon 11, S1613G and M1652I in exon 16; BRCA2:
7470A>G in exon 14) previously identified in other pop-
ulations and reported in the BIC. These polymorphisms
were observed in similar frequencies for both patients and
controls.
No sequence alterations were observed in male and bilat-
eral breast cancer patients.
Frame-shift mutations in BRCA1
Three previously reported deleterious frame-shift muta-
tions resulting in a premature termination codon were
identified in BRCA1: 185delAG in exon 2; 3596del4 and
4184del4 in exon 11). These mutations were not observed
in the control group.BMC Medical Genetics 2006, 7:75 http://www.biomedcentral.com/1471-2350/7/75
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The BRCA1 185delAG mutation was identified in an early
onset index case [age 35] without any family history. This
mutation is common in Ashkenazi Jews, having attained
a 1% carrier frequency within the population [33] since
origin of the ancestral mutation [34]. Population studies
have shown that the 185delAG mutation predates the sep-
aration of Sephardi and Ashkenazi Jewish populations
and is probably 2000 years old [35].
In India, 185delAG has been reported in all populations
studied (Table 4) [26-30]. This deleterious frame shift
mutation was first reported in a family residing in a part
of Trivandrum not far from the small towns with settle-
ment of Jewish people [26]. It was later reported in two
South Indian families from Kerala province [29] as well as
in two sisters from Goa, where a multi-ethnic population
exists, with a significant influence of Portuguese (poten-
tial introduction of the mutation through Sephardic Jews)
[30]. Surprisingly, we have found 185delAG in a North
Indian Hindu patient residing in New Delhi who claimed
to have no Jewish ancestry. Similarly, Lakhotia et al., in
their initial screening found the same mutation in four
Indian breast cancer families [36]. In addition to the
clearly established founder effect for 185delAG, this
mutation has been shown to have arisen independently at
least twice [37], thus it would be interesting to evaluate
the origin and population genetics of these disease suscep-
tibility alleles in the Indian population through haplotype
analysis, given the diverse multilingual, multireligious,
and multiethnic roots of our society.
BRCA1 3596del4 was detected in a Muslim index case of
very early onset disease [age 24] without any family his-
tory. Interestingly, the same mutation was reported in a
heterogeneous Italian population intermixed with French,
German, and Slovenian ethnic groups and a large number
of Muslim immigrants [38]. These observations suggest
that 3596del4 might be a common mutation in the Mus-
lim community and might have migrated to the Indian
population through a pool of Muslim immigrants.
The 4184del4 mutation is located towards the C terminus
of BRCA1, within the transcriptional activation domain
[39,40], a region also reported to interact with the BRCA2
protein, which plays an important role in double stranded
break (DSB) repair.
The above mutation was detected in a late onset index
case [age 60] with a strong family history in first-degree
relatives, thus belonging to a high-risk group. Her mother
and three sisters were all affected with breast cancer. Inter-
estingly, the same mutation was identified in the Paki-
stani population. One patient identified with this
mutation was of Punjabi descent, and the other, who
resided in Karachi, identified herself as Sindhi [41]. This
mutation has been reported 107 times in the Breast Can-
cer Information Core (BIC) website in breast cancer cases
of diverse ethnic origins [18]. In a study from northwest
England, it was found that the 4184del4 mutation has at
least three distinct haplotypic backgrounds, implying that
the mutation has occurred independently on at least three
occasions, suggesting this to be a mutational hotspot giv-
ing rise to recurrent mutations [42]. Haplotypic analysis
would be interesting in this case also to determine
whether 4184del4 has an independent origin in the
Indian populaion or whether an existing mutation has
been introduced through population admixture.
Frame-shift mutations in BRCA2
Three protein truncating frame-shift mutations unique to
Indian women (6376insAA, 8576insC, 9999delA) were
observed in the BRCA2 gene.
The BRCA2 frame shift mutation 6376insAA was found in
an index case [age 30] without any family history. This
mutation is located in the BRC repeats encoded in exon
Table 2: BRCA1/BRCA2 deleterious mutations in Indian Breast Cancer patients
Exon Gene NT Base Change Codon AA
Change
Designation Variation type BIC
entry
Case(s)
n = 204
A/S/R* F.H. Control(s)
n = 140
2 BRCA1 185 delAG 23 Stop 39 185delAG Frame-shift
protein truncating
Reported 1 (0.49%) 40/F/H NO 0
11d BRCA1 4184 delTCAA 1355 Stop
1634
4184del4 Frame-shift
protein truncating
Reported 1 (0.49%) 60/F/H 3 Sisters +
Mother Br Ca
0
11d BRCA1 3596 delGAAA 1159 Stop
1208
3596del4 Frame-shift
protein truncating
Reported 1 (0.49%) 24/F/M NO 0
11e BRCA2 6376 Ins AA 2049 Stop
2051
6376InsAA Frame-shift
protein truncating
Novel 1 (0.49%) 30/F/H NO 0
19 BRCA2 8576 Ins C 2783 Stop
2797
8576InsC Frame-shift
protein truncating
Novel 1 (0.49%) 35/F/H NO 0
27B BRCA2 9999 del A 3258 Stop
3275
9999delA Frame-shift
protein truncating
Novel 1 (0.49%) 50/F/H NO 0
*A-age of diagnosis; S-sex; R-religion (H-Hindu; M-Muslim) Br Ca-Breast Cancer.BMC Medical Genetics 2006, 7:75 http://www.biomedcentral.com/1471-2350/7/75
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11. These eight 30–40 residue motifs are conserved
between several mammalian species, and have been
shown to mediate binding of BRCA2 to the RAD51 pro-
tein, a mammalian protein essential for DNA repair and
genetic recombination [43].
BRCA2 8576insC  in exon 19 was detected in an early
onset index case [age 35] without any family history.
The third mutation, 9999delA in exon 27B, was found in
a late onset case [age 50], also without any family history.
Missense mutations in the BRCA1/2 genes
Apart from common polymorphisms, only a single mis-
sense mutation each was detected in BRCA1 and BRCA2.
Neither mutation was detected in any control samples
(280 chromosomes).
A novel BRCA1  missense, K1667R, along with a silent
alteration 1679L in exon 17 was observed in the same
high-risk index case [age 35] with a strong family history
in first-degree relatives, thus suggesting its disease associ-
ation.
One BRCA2 missense alteration A2951T was observed in
exon 22. This mutation was observed in only one index
case [age 40] without any family history. Originally
reported as a polymorphism with a modest carrier fre-
quency of 0.006 in an American population [44], our fail-
ure to detect this variant in any control samples suggests
that this alteration may not represent a common poly-
morphism in the North Indian population.
Functional significance
Missense mutations may be pathogenic, depending upon
the nature of the amino acid substitution and its effect on
protein structure or function. In general, missense altera-
tions in conserved protein motifs are more likely to be
deleterious. Missense amino acid changes in the p53-
binding domain or the transactivation domain of BRCA1
adjacent to a BRCT repeat have been shown to be patho-
genic [45,46]. Interestingly, the BRCA1 missense altera-
tion K1667R is located in the BRCT domain. These
conserved motifs are found in many other proteins, and
are involved in DNA repair and cell cycle regulation.
Tumor associated mutations are predicted to disrupt the
folding or stability of the BRCT domain and thus effect
protein function [46].
Non-conservative amino acid substitutions may disrupt
protein folding, and BRCA2 A2591T leads to substitution
of the non-polar hydrophobic amino acid alanine by
polar hydrophilic threonine. However, although A2951 is
invariant in vertebrate species through puffer fish, suggest-
ing strong evolutionary conservation due to functional
constraints, the frequency of this variant in disease-free
individuals is counter indicative, and additional data are
required to evaluate potential disease-association of this
allele.
In addition to missense mutations, many variants outside
of the exonic amino acid coding sequences were identi-
fied. One intriguing BRCA1  alteration, 22 C>G, was
observed in the 5'UTR region which contains a consensus
sequence of 5'-CCAGCCAUG-3' involved in the initiation
of protein synthesis. This variant was detected in one
patient but was absent in the control group. It may be pos-
sible that this mutation interferes with normal transla-
tional initiation of BRCA1, giving rise to a hypomorphic
allele that may confer some risk of breast cancer; however,
the exact functional significance remains uncertain.
While the exact functional relevance of the intronic vari-
ants identified in our study is not known, they may lead
to aberrant splicing, either through alteration of consen-
sus splice sites or other splice enhancer sequences. Exon
skipping, the most frequent outcome, is thought to result
from failure of the mutant splice sites to define an exon.
BRCA1 IVS13 (+2) T>C in exon 13 was identified in the
present study as well as in another patient in the previous
pilot study [27]. This variant is within the consensus splice
donor sequence, and hence could lead to aberrant splic-
ing. Evaluating the effect of this variant on BRCA1 mRNA
processing could support its functional significance. How-
ever, this awaits resampling of the respective mutation
carriers, as at present, tissue samples for these patients are
available only in the form of paraffin embedded blocks.
Summary
We observed 9  distinct  BRCA1  and  9  distinct BRCA2
sequence variants; 4 of the 9 BRCA1 (44%) and 7 of the 9
BRCA2 mutations (78%) are unique to the Indian popu-
lation and are distributed throughout the exons of BRCA1
and BRCA2 gene. Of these 18 mutations, six clearly dele-
terious sequence variants were detected in 2.94% of the
tested patients. The prevalence of BRCA1/2 mutations in
our Indian patient series appears to be low compared to
other Asian countries [[41,47] and [48]] but is compara-
tively similar to that reported from Shanghai China [49].
In addition, similar mutation frequencies were observed
in series of early onset breast cancer cases in Britain [50].
It is possible that of the further 13 variants of uncertain
clinical significance identified in 15 additional patients,
some may be disease causal. These variants can be further
evaluated in order to classify them into high- or low-risk
categories based on epidemiological observations includ-
ing degree of family history and segregation of the variant
with disease. Additional classifiers include amino acidB
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Table 3: BRCA1/BRCA2 sequence variants of unknown significance and known polymorphisms in Indian Breast Cancer patients
Exon Gene NT Base Change Codon AA Change Designation Variation type BIC entry Case(s)
n = 204
A/S/Ra Family History Control(s)
n = 140
1 BRCA1 22 C>G 5'UTR - 22C>G Transition UV Novel 1 (0.49%) 35/F/H NO 0
7 BRCA1 560 T>C Non coding - IVS7+38 T>C Transversion Intronic, UV Novel 1 (0.49%) 30/F/H NO 0
11a BRCA1 790 delG Non coding - IVS10-12delG Deletion Intronic, UV Reported 4 (1.96%) 35/F/H
35/F/H
35/F/H
31/F/H
NO
NO
NO
NO
0
11d BRCA1 3668 A>G 1183 Lys to Arg K 1183 R Polymorphism Reported 16 (7.84%) - - 25 (20.8%)b
13 BRCA1 4476 T>C Non coding - IVS13+2 T>C Transversion Intronic, UV Reported 1 (0.49%) 30/F/H NO 0
16 BRCA1 4956 A>G 1613 Ser to Gly S1613G Polymorphism Reported 1 (0.49%) 62/F/H NO 2 (1.7%)b
16 BRCA1 5075 G>A 1652 Met to Ile M1652I Polymorphism Reported 14 (6.86%) - - 10 (8.3%)b
17 BRCA1 5119
5154
A>G
C>T
1667
1679
Lys to Arg
Leu to Leu
K1667R
5154 C>T
Transversion, Missense UV
Transversion Silent, UV
Novel
Novel
1 (0.49%)
1 (0.49%)
35/F/H Mother +Sister Br Ca 0
0
2 BRCA2 295 T>A Non coding - IVS2+90 T>A Transition Intronic, UV Novel 1 (0.49%) 32/F/H NO 0
7 BRCA2 859 A>T Non coding - IVS 7+75A>T Transition Intronic, UV Novel 1 (0.49%) 32/F/H NO 0
8 BRCA2 909 C>T Non coding - IVS 8+56C>T Transversion, Intronic, UV Novel 1 (0.49%) 52/F/H Grand-Mother Br Ca 0
10B BRCA2 1593 A>G 455 Ser to Ser 1593A>G Transversion Silent, UV Reported 1 (0.49%) 48/F/H NO 0
14 BRCA2 7470 A>G 2414 Ser to Ser 7470A>G Polymorphism Reported 24 (11.8%) - - 32 (26.7%)b
22 BRCA2 9079 G>A 2951 Ala to Thr A2951T Transition Missense Reported 1 (0.49%) 40/F/H NO 0
25 BRCA2 9729 insG Non coding - IVS25+58InsG Substitution Intronic, UV Novel 3 (1.47%) 45/F/H
30/F/H
24/F/H
NO
NO
Sister Br Ca
0
aA-age of diagnosis; S-sex; R-religion (H-Hindu; M-Muslim).
bCarrier frequency calculated from 120 controls, UV – unclassified variant, Br Ca-Breast Cancer.B
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) Table 4: BRCA1/BRCA2 mutations and sequence variants reported in Indian populations.
Gene aExon aNucleotide 
change
aAmino acid 
change
bMutation type cMutation 
effect
Reported in 
BIC
dSaxena 
(2002);
n = 20
dSaxena 
(2006);
n = 204
dKumar 
(2002);
n = 14
dValarmathi 
(2002);
n = 13
dValarmathi 
(2004);
n = 16
dHedau (2005);
n = 124
BRCA1 1 22 C>G 5'UTR UV No SC (35)
BRCA1 2 185 delAG fs23 Stop 39 FS PT Yes SC (40) ≥ 1 FDR br/ov F01: br 
(40,35,34) F09: 
br 
(51,59,45,54,4
5,30) ov (51)
FH+
BRCA1 2 147 G>A Glu 10 Lys MS UV No patient/
obligate carrier
BRCA1 2 186 G>A Glu 23 Lys MS UV No patient/
obligate carrier
BRCA1 IVS-5 331+1 G>T SS UV Yes FH+(30) 
br(36) ov(46)
BRCA1 7 465 G>A Glu 116 Lys MS UV No ≥1 FDR br/ov
BRCA1 7 448 A>C Lys 110 Thr MS UV No FH+(40)
BRCA1 7 459 T>C Ser 114 Pro MS UV No FH+(35)
BRCA1 IVS-7 560+38 T>C NC UV No SC (30)
BRCA1 IVS-7 561-34 C>T NC PM Yes co-occurrence 
B1:185delAG
BRCA1 IVS-10 790-12 delG NC UV No SC (35)
SC (35)
SC (35)
SC (31)
BRCA1 11 1027 delA fs303 Stop313 FS PT No ≥1 FDR br/ov
BRCA1 11 3596 del4 fs1159 
Stop1159
FS PT Yes SC (24)
BRCA1 11 3667A>G Lys1183Arg MS PM Yes 8% patients; 
21% controls
patients and 
controls
BRCA1 11 3672 G>T Glu 1185 Stop NS PT No F08: br (36,45)
BRCA1 11 3679 G>T Ser 1187 Ile MS UV Yes patient/
obligate carrier
BRCA1 11 3730 G>T
3740 G>C
Arg 1204 Ile
Lys 1207 Asn
MS
MS
UV
UV
No
No
F12: patient 
co-occurrence
BRCA1 11 3769C>A Ser 1217 Tyr MS UV No patient/
obligate carrier
BRCA1 11 3867 G>T Glu 1250 Stop NS PT Yes F1: br 
(42,40,34)
BRCA1 11 3797 C>G
3846 A>G
Phe1226Leu
Arg1243Gly
MS
MS
UV
UV
No
No
F09: patient 
co-occurrence
BRCA1 11 4184del4 fs1355 
Stop1364
FS PT Yes FH+ (60) br: 
(M,3S)
BRCA1 12 4302 C>T Gln 1395 Stop NS PT Yes FH+(40)
BRCA1 IVS-13 4476+2T>C SS UV No SC(30) SC (30)
BRCA1 16 4956 A>G Ser 1613 Gly MS PM Yes 0.5% patients; 
1.7% controls
BRCA1 16 5075 G>A Met 1652 Ile MS UV Yes 6.9% patients; 
8.3% controls
BRCA1 16 4956 insG fs1613 
Stop1621
FS PT No FH+(45)B
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BRCA1 17 5119 A>G
5154 C>T
Lys 1667 Arg
Leu 1679 Leu
MS
silent
UV
UV
No FH+ (35) br: 
(M, S) co-
occurrence
BRCA1 IVS-18 5271+66A>G NC PM Yes co-occurrence 
B1:185delAG
BRCA1 20 5341 T>G Val 1741 Gly MS UV No 2.7% controls
BRCA1 20 5364 C>G Pro 1749 Ala MS UV No FH+ (30)
FH+ (38)
BRCA1 20 5379 G>T Glu 1754 Stop NS PT Yes F2: 
br(40,39,32,29,
27)
BRCA2 2 203 G>A 5'UTR PM Yes patients and 
controls
patients and 
controls
BRCA2 IVS-2 295+90 T>A NC UV No SC (32)
BRCA2 IVS-3 545-54C>G NC PM No patients and 
controls
BRCA2 IVS-7 859+75A>T NC UV No SC (32)
BRCA2 IVS-8 909+56C>T NC UV Yes FH+ (52) br: 
(GM)
BRCA2 10 1593A>G Ser 455 Ser silent PM Yes SC (48)
BRCA2 11 5227dupT
5639T>C
5929G>A
fs1667 
Stop1676
Val1804Ala
Glu1901Lys
FS
MS
MS
PT
UV
UV
No
No
No
F11: br (24) 
co-occurrence
BRCA2 11 5242dupT FS PT No F03: br 
(45,41,28) ov 
(63)
BRCA2 11 6180dupA fs1984 
Stop2002
FS PT No F02: br 
(39,40,32,29,2
7)
BRCA2 11 5624C>T
6515C>T
Thr 1679 Ile
Pro 2096 Leu
MS
MS
UV
UV
No
No
F12: br (36,45) 
co-occurrence
BRCA2 11 5007A>C Glu 1593 Asp MS UV Yes MBC(45)
SC(32) not in 
cotrols
BRCA2 11 6376 ins AA fs2049 
Stop2051
FS PT No SC (30)
BRCA2 14 7470A>G 
(PM)
Ser 2414 Ser silent PM Yes 11.8% patients; 
26.7% controls
BRCA2 18 8345A>G Asn 2706 Ser MS UV Yes SC(30) 
B1:IVS13 co-
occurrence
FH+(60) 
br(35,40) not 
in controls
-
BRCA2 19 8576 insC fs2783 
Stop2797
FS PT No SC (35)
BRCA2 22 9079 G>A Ala 2951 Thr MS PM Yes SC (40)
BRCA2 IVS-25 9729+58InsG
G
NC UV No FH+ (24) br: S
SC (30)
SC (45)
BRCA2 27B 9999delA fs3258 
Stop3275
FS PT No SC (50)
aGenbank BRCA1-HSU14680; Genbank BRCA2-; IVS – intervening sequence-intron number;
bUTR – untranslated region; NC – non-coding; FS – frame shift; MS – missense; NS – nonsense.
cSS – splice site; PT – protein truncating; MS – missense; UV – unclassified variant; PM – polymorphism.
dn is the total number of independent families studied; (age of dx.); FH+ – family history present (M-mother, S-sister; GM-grandmother); FDR – first degree relative; MBC-male breast cancer; SC – sporadic cases; 
br – breast cancer; ov – ovarian cancer; br/ov – breast, breast-ovarian or ovarian cancer
Table 4: BRCA1/BRCA2 mutations and sequence variants reported in Indian populations. (Continued)BMC Medical Genetics 2006, 7:75 http://www.biomedcentral.com/1471-2350/7/75
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conservation, severity of amino acid change and evidence
from functional assays [51].
In this study, scanning for the presence of sequence varia-
tion was performed by analyzing PCR amplicons using gel
based HDX. It is estimated that the mutation detection
sensitivity of the heteroduplex method utilized is approx-
imately 80% [52]. Although the sensitivity of this
approach is lower than some other mutation analysis
techniques (e.g dHPLC, direct sequencing), it is relatively
inexpensive, reasonably high throughput, technically sim-
ple to perform, and has been applied successfully for
numerous genetic disorders – including BRCA1  and
BRCA2 screening [31]. To increase the efficacy of muta-
tion detection, the screening for mutations in both the
genes was repeated by HDX in all familial cases. Moreover
no currently available technique can guarantee 100%
detection of pathogenic mutations in the BRCA1 and
BRCA2 genes. In particular, all PCR based methods are
unable to detect large genomic rearrangements that occur
frequently in both genes and can account for a significant
proportion of BRCA1/BRCA2 mutations [53-59].
Nevertheless, the number of clearly disease-associated
mutations identified in the studied North-Indian popula-
tion is lower than observed elsewhere. However, a signifi-
cant proportion of women who had breast cancer
diagnosed at age ≤40 years without any family history
were carriers (all variants: 14.2%, known deleterious
mutations: 3.8%). On the other hand, the identified
mutations account for a comparatively small proportion
of the familial risk of breast cancer (all variants: 11.7%,
known deleterious mutations: 2.9%). This suggests one of
several possibilities with respect to genetic predisposition
in the North Indian population. First, there may be a sig-
nificant proportion of BRCA1/2 mutations that are large
germ line rearrangements, which would not have been
detected by the method of mutation screening employed.
Second, it is possible that there are some unknown genes,
which may contribute more significantly to familial breast
carcinoma in this population than do BRCA1 and BRCA2.
The present study is in agreement with the findings from
our pilot study done on a small independent group of 20
breast cancer patients where 3 out of 5 cases with muta-
tions in BRCA1/2 had early onset disease [27]. Thus, it is
reasonable to postulate that women with early-onset dis-
ease without family history are likely to have a disease
associated alteration of the BRCA1 or BRCA2 gene. A sim-
ilar viewpoint has been put forwarded by a study con-
ducted on Iranian women where it concluded that early
onset breast cancer with a limited family history or with-
out family history [60] is sufficient to justify mutation
screening. It is possible that the significant number of
early onset patients without reported family history have
BRCA1/2 germ line mutations that are paternally inher-
ited. In many cultures, knowledge of family history of dis-
ease is better documented along matrilineal lines,
particularly those diseases that are gender restricted.
A possible explanation for the earlier age of disease onset
in BRCA1/2 mutation carriers could be high circulatory
estrogen levels in younger women compared to elderly
women. According to one hypothesis, the total number of
ovulatory cycles and thus exposure to higher estrogen
level is a significant factor contributing to the risk of breast
cancer [61]. Estrogen exposure is hypothesized to increase
the susceptibility to breast tissue to carcinogenesis
through continued cell division and proliferation result-
ing from multiple ovulatory cycles, principally between
menarche and first birth, thus allowing for a concomitant
increase in the accumulation of random genetic errors
[62,63]. Increased estrogenic exposures increase the rate
of proliferation, hence magnifying the effect. Studies have
shown that wild-type BRCA1  blocks estrogen receptor
(ER) mediated transcriptional activation, thereby inhibit-
ing estrogenic signalling [64]. These observations could
account for the higher proportion of early-onset breast
cancer in populations where exposures to risk factors that
primarily influence post-menopausal breast cancer risks
are, as yet, relatively low.
Extensive mutation screening of high-risk breast cancer
primarily targeting early-onset cases should be under-
taken in India with proper genetic counseling, since
female carriers of mutations in these genes are also at a
high risk for developing a second malignancy either in the
breast or ovary. Personal risk information may help in tak-
ing preventive measures and also motivate a high-risk
woman to adopt breast screening that may promote early
detection and improve chances of surviving breast cancer.
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